Intralymphatic immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 9, Issue 6, 2009, Pages 537-543

  Senti, Gabriela ^a   Johansen, Pål ^b   Kündig, Thomas M ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Allergen; Immunotherapy; Intralymphatic; Vaccination

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; BEE VENOM; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PLASMID DNA; PROTEIN;

CONTROLLED STUDY; DENDRITIC CELL; HAY FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INTRALYMPHATIC DRUG ADMINISTRATION; INTRALYMPHATIC IMMUNOTHERAPY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT DURATION; TUMOR CELL;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INJECTIONS, INTRALYMPHATIC; LYMPHOCYTE ACTIVATION; PATIENT COMPLIANCE; TIME FACTORS;

EID: 70350776595     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283310ff7     Document Type: Review

References (76)

1. Kundig TM, Bachmann MF, DiPaolo C, et al. Fibroblasts as efficient antigenpresenting cells in lymphoid organs. Science 1995; 268:1343-1347.
2. Zinkernagel RM, Ehl S, Aichele P, et al. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997; 156:199-209.
3. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000; 12:163-171.
4. Greter M, Hofmann J, Becher B. Neo-lymphoid aggregates in the adult liver can initiate potent cell-mediated immunity. PLoS Biol 2009; 7:e1000109.
5. Karrer U, Althage A, Odermatt B, et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J Exp Med 1997; 185:2157-2170.
6. Frey JR, Wenk P. Experimental studies on the pathogenesis of contact eczema in the guinea-pig. Int Arch Allergy Appl Immunol 1957; 11:81-100.
7. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38:1404-1413.
8. Johansen P, Haffner AC, Koch F, et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005; 35:568-574.
9. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci U S A 2001; 98:3299-3303.
10. Martinez-Gomez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009; 150:59-65.
11. Barratt-Boyes SM, Zimmer MI, Harshyne LA, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cellbased vaccines. J Immunol 2000; 164:2487-2495.
12. Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8p T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006; 55:469-474.
13. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59:3340-3345.
14. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-58.
15. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63:12-17.
16. Lesimple T, Moisan A, Carsin A, et al. Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol Immunother 2003; 52:438-444.
17. Quillien V, Moisan A, Carsin A, et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 2005; 32:731-741.
18. Thomas R, Chambers M, Boytar R, et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 1999; 9:474-481.
19. Barratt-Boyes SM, Watkins SC, Finn OJ. Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. Adv Exp Med Biol 1997; 417:71-75.
20. West E, Morgan R, Scott K, et al. Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immunother 2009; 32:66-78.
21. Lesimple T, Neidhard EM, Vignard V, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006; 12:7380-7388.
22. Mackensen A, Krause T, Blum U, et al. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34p hematopoietic progenitor cells. Cancer Immunol Immunother 1999; 48:118-122.
23. Grover A, Kim GJ, Lizee G, et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006; 12:5801-5808.
24. Brown K, Gao W, Alber S, et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 2003; 171:6875-6882.
25. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23:1407-1413.
26. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166:4254-4259.
27. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-1064.
28. Juillard GJ, Boyer PJ. Intralymphatic immunization: current status. Eur J Cancer 1977; 13:439-440.
29. Juillard GJ, Boyer PJ, Niewisch H, Hom M. Distribution and consequences of cell suspensions following intralymphatic infusion. Bull Cancer 1979; 66:217-228.
30. Juillard GJ, Boyer PJ, Snow HD. Intralymphatic infusion of autochthonous tumor cells in canine lymphoma. Int J Radiat Oncol Biol Phys 1976; 1:497-503.
31. Juillard GJ, Boyer PJ, Yamashiro CH. A phase I study of active specific intralymphatic immunotherapy (ASILI). Cancer 1978; 41:2215-2225.
32. Juillard GJ, Boyer PJ, Yamashiro CH, et al. Regional intralymphatic infusion (ILI) of irradiated tumor cells with evidence of distant effects. Cancer 1977; 39:126-130.
33. Heinzerling L, Basch V, Maloy K, et al. Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. Vaccine 2006; 24:1389-1394.
34. Smith KA, Tam VL, Wong RM, et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009; 27:2603-2615.
35. Weber J, Boswell W, Smith J, et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008; 31:215-223.
36. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer 2003; 98:144-154.
37. Sigel MB, Sinha YN, VanderLaan WP. Production of antibodies by inoculation into lymph nodes. Methods Enzymol 1983; 93:3-12.
38. Nilsson BO, Svalander PC, Larsson A. Immunization of mice and rabbits by intrasplenic deposition of nanogram quantities of protein attached toSepharose beads or nitrocellulose paper strips. J Immunol Methods 1987; 99:67-75.
39. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2:767-775.
40. Kawabata S, Miller CJ, Lehner T, et al. Induction of Th2 cytokine expression for p27-specific IgA B-cell responses after targeted lymph node immunization with simian immunodeficiency virus in rhesus macaques. J Infect Dis 1998; 177:26-33.
41. Lehner T, Mitchell E, Bergmeier L, et al. The role of gammadelta T cells in generating antiviral factors and beta-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur J Immunol 2000; 30:2245-2256.
42. Bogers WM, Bergmeier LA, Ma J, et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. AIDS 2004; 18:25-36.
43. Bogers WM, Bergmeier LA, Oostermeijer H, et al. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine 2004; 22:2974-2984.
44. Klavinskis LS, Bergmeier LA, Gao L, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virusspecific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996; 157:2521-2527.
45. Lehner T, Bergmeier LA, Tao L, et al. Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 1994; 153:1858-1868.
46. Finerty S, Stokes CR, Gruffydd-Jones TJ, et al. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 2001; 20:49-58.
47. Guidry AJ, O'Brian CN, Oliver SP, et al. Effect of whole Staphylococcus aureus and mode of immunization on bovine opsonizing antibodies to capsule. J Dairy Sci 1994; 77:2965-2974.
48. von Beust BR, Johansen P, Smith KA, et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 2005; 35:1869-1876.
49. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10:187-192.
50. Storni T, Ruedl C, Schwarz K, et al. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004; 172:1777-1785.
51. Bourquin C, Anz D, Zwiorek K, et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008; 181:2990-2998.
52. Koopman G, Bogers WM, van Gils M, et al. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 2007; 79:474-482.
53. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005; 116:377-383.
54. Verlato G, Corsico A, Villani S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol 2003; 111:1232-1238.
55. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225-1232.
56. Wuthrich B, Schindler C, Medici TC, et al. IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. Int Arch Allergy Immunol 1996; 111:396-402.
57. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-562. (Pubitemid 28487930)
58. Lockey RF. 'ARIA': global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001; 108:497-499.
59. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302:265-269.
60. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grasspollen immunotherapy. N Engl J Med 1999; 341:468-475.
61. Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-587.
62. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
63. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256.
64. Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:660-677.
65. Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera Venom study. Part III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990; 86:775-780.
66. Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992; 90:567-578.
67. Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann Allergy Asthma Immunol 2000; 84:241-243.
68. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113:1025-1034; quiz 35.
69. Norman PS. Immunotherapy: 1999-2004. J Allergy Clin Immunol 2004; 113:1013-1023; quiz 24.
70. Vissers JL, van Esch BC, Hofman GA, et al. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol 2004; 113:1204-1210.
71. Johansen P, Senti G, Martinez Gomez JM, et al. Toll-like receptor ligands as adjuvants in allergen-specificimmunotherapy. Clin Exp Allergy2005; 35:1591-1598.
72. Johansen P, Senti G, Martinez Gomez JM, et al. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol 2005; 35:3591-3598.
73. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008; 105:17908-17912.
74. Rhyner C, Kundig T, Akdis CA, Crameri R. Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 2007; 35:833-834.
75. CrameriR, Fluckiger S, Daigle I, et al. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007; 62:197-206.
76. Martinez-Gomez JM, Johansen P, Rose H, et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009; 64:172-178.